“It highlights the critical need for the Administration and Congress to act swiftly to restore the ability of Mexican nationals to enter this country to donate plasma used to produce life-saving therapies,” he said.

“Leaving CBP’s policy in place will continue to exacerbate the shortage of plasma and damage public health. We will file notice to appeal this decision immediately.”

CSL shares dropped 2.6 per cent to $290.05 on Monday morning. The company has warned margins will be under pressure in the coming year in light of the increasing costs of collecting plasma. In the United States, donors are paid upwards of $US50 for their time, but these amounts have increased over the past year in a bid to attract citizens back into centres after periods of shutdowns and heavy government stimulus during the pandemic.

CSL reported a full-year profit of $US2.4 billion in 2021, but is guiding to lower profits of between $US2.15 billion and $US2.25 billion in 2023.

The Market Recap newsletter is a wrap of the day’s trading. Get it each weekday afternoon.